408 results about "Elevated creatinine" patented technology

A method for treating patients with renal failure includes administering to them an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta. Soluble cytokine receptors also can be employed. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof The composition can be included in a kit.

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention discloses a two-step enzyme measuring method and measuring reagents for creatinine in blood serum. The hydrogen peroxide generated by endogenous creatine is eliminated by utilizing catalase in a reagent 1 of the creatinine measuring reagents, and the catalase in the reagent 1 is suppressed by utilizing the catalase in a reagent 2 of the creatinine measuring reagents, so that the creatinine content in a sample is measured. The invention has the advantages that the phenomenon that the cost is increased because of oxidizing hydrogen peroxide by the catalase, so that the detection result is low in accuracy and precision is avoided.

The invention belongs to the chemical field of natural products and particularly relates to a preparation method and use of moringa oleifera leaf polysaccharides. The preparation method comprises the steps of carrying out combined microwave-ultrasound extraction, hydrochloric acid method deproteinization, hydrogen peroxide method decoloration and AB-8 macroporous adsorption resin column separation, so as to prepare the moringa oleifera leaf polysaccharides. The preparation method of the moringa oleifera leaf polysaccharides has the advantages of short extraction time, low extraction temperature, low energy consumption and high extraction rate and purity. Besides, an animal experiment proves that the prepared moringa oleifera leaf polysaccharides have remarkable treatment effect to hyperuricosuria; by decreasing the content of cholesterol, triacylglycerol, urea nitrogen, creatinine and xanthine oxidase, the production of uric acid is achieved; meanwhile, by directly decomposing uric acid, renal functions are improved, the excretion of uric acid is promoted, and blood vessels are protected, thereby being favorable to the recovery of patients with the hyperuricosuria. The preparation method has a wide medical application prospect.

The invention discloses a system for estimating the state of a critically ill patient in an obstetrical department, which comprises an input end, an output end and a data processing module. Firstly, measured heart rate, blood pressure, body temperature, breathing rate, pH, blood HCO-3 concentration, oxygen partial pressure, alveolar arterial blood oxygen tension difference, potassium ion concentration, hematokrit, white cell count, platelet count, fibrinogen, glutamic-oxaloacetic transaminase, albumin, bilirubin, creatinine, blood glucose concentration and nervous system grading data are input the system through the input end; the data processing module evaluates a death risk factor; and at last, the output end directly reflects the result of the patient and the expert suggestion. The invention can not only accurately evaluate the critical degree of the state of the patient and predict the death risk, but also can provide quantitative indexes for changing to a three-class hospital, and is beneficial to improve the treatment level of the critical state of the obstetrical department and lower the death rate of pregnant and lying-in women and perinatal infants.

Provided herein are flexible, microfluidic epidermal systems and methods useful in the analysis of biofluids for biomarkers corresponding to a variety of conditions and methods of use. The provided systems configured to create conformal contact with the skin to allow for medical testing or screening, either in situ or later external laboratory testing. The described devices and methods may be used for cystic fibrosis screening, glucose monitoring, drug and / or alcohol testing, creatinine monitoring, urea monitoring, pH measurement and dialysis treatment efficacy testing.

An improved optical sensor and method for measuring concentration of a chemical constituent where measurement interference from other chemical compounds is present in the solution is provided. More specifically, the invention relates to a system for measuring the amount of creatinine in effluent dialysate during, before, or following a kidney dialysis procedure and a method for using the same. Alternatively, the method may be used with blood and other body fluids or solutions that contact the patient. The system may use an enzyme or other chemical process to specifically remove or convert an analyte with an intrinsic optical absorbance. By measuring the absorbance before and after the chemical process the analyte can be measured with high accuracy and specificity. The method may be extended to multiple analyte measurements using cascaded chemical processes.

The invention discloses a sepsis early prediction method based on machine learning. The method comprises the following steps: firstly, extracting clinical data, including demographic statistics (suchas age and gender), vital sign variables (such as heart rate and systolic pressure) and laboratory measurement indexes (such as creatinine and platelet count), of a patient within 24 hours after a patient enters an ICU by utilizing an electronic medical record, preprocessing the data, inputting the preprocessed data into an improved deep forest algorithm model for training, and outputting the disease probability of the patient after training optimization. And meanwhile, the algorithm model can also sort characteristic variables and output an early warning factor which has great influence on early prediction of sepsis. Finally, corresponding variables of the patient needing to be predicted are input into the trained model, so that early prediction of sepsis can be carried out on the patient. According to the invention, early prediction is carried out on sepsis based on a machine learning method, doctors can be assisted in making clinical decisions, and the prediction accuracy is improved.

The invention discloses a creatinine detection reagent which is characterized by comprising a diluent and a reaction reagent, wherein the diluent is composed of buffer, surfactant, preservative, anti-bilirubin interference agent and vitamin C oxidase; and the reaction reagent is composed of buffer, creatinase, sarcosine oxidase, peroxidase, N-ethyl-N-(3-propylsulfo)-3-methylaniline, creatininase, 4-aminoantipyrine, preservative and freeze-drying protective agent. The detection reagent disclosed by the invention has favorable sensitivity, accuracy, precision and linearity, and can completely satisfy the clinical examination requirements.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

The present invention relates to methods of treating subjects preparing to undergo surgery or methods of treating chronic disease and methods for reducing transfusions and a computer readable storage medium and a physical computing device for carrying out these methods which include: a) receiving a profile of said subject, in a physical computing device, including a level of hemoglobin of said subject, level of creatinine of said subject, and information regarding current or past history of disease; b) applying said level of hemoglobin and said level of creatinine, in said physical computing device, to determine level of transfusion risk; c) applying said information regarding current or past history of disease of said subject, in said physical computing device, to determine level of comorbidity; d) applying said level of hemoglobin, said level of transfusion risk, and said level of comorbidity, in said physical computing device, to determine a patient care plan.

The invention discloses a serum creatinine detecting reagent, and belongs to the technical field of clinical in-vitro detection. According to the serum creatinine detecting reagent, gamma-Fe2O3 nano-particles are added into a reagent R1, so that the activity of peroxidase and the specificity to a substrate are enhanced, and the interferences of reducing substances, such as ascorbic acid, uric acid, glutathione and bilirubin, are reduced; meanwhile, the gamma-Fe2O3 nano-particles also serve as a catalyst of a reaction; the interference of endogenous creatine is effectively eliminated by the combination action of the gamma-Fe2O3 nano-particles and the peroxidase. In addition, the serum creatinine detecting reagent adopts N-ethyl-N-(2-hydroxy-3-sulfonated propyl)-3-methylaniline sodium salt (TOOS) as a chromogen, so that the reagent is more stable; the analysis sensitivity is high. The substances, such as lipase and lipoprotein lipase, are also added into the reagent R1, so that the influence of lipid turbidity can be removed effectively; therefore, the reagent of the invention has higher anti-jamming capability and stability.

The invention provides a kit for simultaneously detecting sodium, creatinine and microalbumin in urine. The kit comprises a reaction substrate with a sodium reaction hole, a creatinine reaction hole and a microalbumin reaction hole, and sodium diluent, creatinine diluents and standard colorimetric plates for sodium, creatinine and albumin. Reaction mats containing different configuration substrates and enzyme solutions are added to the three reaction holes, and semiquantitative detection on sodium, creatinine and microalbumin in urine is achieved. The kit is simple in preparation method, stable in performance and easy to store, color gradations corresponding to the content of sodium, creatinine and microalbumin in different kinds of urine are obvious, whether the salt amount of a detected person exceeds the standard or not and whether the kidney is damaged or not can be conveniently judged, and meanwhile the kit is suitable for being used by the clinical laboratory in a hospital and non-professional inspection personnel.

The invention generally relates to devices, systems and methods adapted for use by patients for monitoring their own dietary intake of sodium without any need of laboratory facilities or collection of blood samples. The systems utilize test strips for measuring the concentration of analytes in urine, specifically, chloride and creatinine. Urinary chloride concentrations, normalized by creatinine concentrations to reduce variability contributed mainly by changing states of hydration serve as a conveniently monitored surrogate for salt intake by subjects, especially patients with hypertension or congestive heart failure who must control their salt intake carefully.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention belongs to the technical field of metabonomics, and provides Xiaoyao San metabolic markers in a biological sample, and a detection method and an application thereof. A pharmacological action mechanism of Xiaoyao San for treating depression is defined. The metabolic markers are 4-oxo hex-2-ene dioic acid, creatinine, L-cystathionine and acetylphosphate. A UPLC-Q-TOF / MS technology is adopted for analyzing the plasma and metabolic profile change of patients in a drug administration group and a control group of the Xiaoyao San, and then a multivariate statistical analysis method and an orthogonal partial least square discriminant analysis (OPLS-DA) method are adopted for screening the changes of the metabolic markers of the Xiaoyao San after 8-week treatment. The study is used as a first clinical metabonomics study of the Xiaoyao San; the influence of the metabolic level of the Xiaoyao San is found; the action mechanism of the Xiaoyao San is preliminarily illuminated in metabolic pathway; and a new method is provided for predicting the pharmacological mechanism of the Xiaoyao San for treating the depression.

The invention belongs to the technical field of biology and particularly discloses selenium-rich bifidobacterium longum as well as a preparation method and application thereof. The selenium-rich bifidobacterium longum prepared by virtue of the preparation method can be applied to the preparation drugs or foods for delaying the progress of diabetes mellitus and particularly can be applied to the preparation of the drugs or the foods for improving the physical signs and metabolism conditions of diabetes mellitus, the insulin signal pathways of a diabetes mellitus model, the pathological change of livers, pancreas and kidneys of patients with diabetes mellitus and the levels of serum creatinine and blood urea nitrogen of diabetes mellitus and preventing renal complications or renal function damage of diabetes mellitus.

The invention relates to an analysis method for quickly detecting urine creatinine by isotopic dilution, extractive electrospray ionization (EESI) and tandem mass spectrometry (MS / MS), and belongs to an analysis and detection means for a renal function biomarker. The method is characterized in that the detection means is that an EESI source is subjected to direct MS and MS / MS under normal pressure, linear trap quadrupole (LTQ)-MS / MS is set to be in a positive ion detection mode, the parameters of the EESI source, such as the composition of an electrospray solvent are adjusted, an isotopic dilution technology and a standard addition method are adopted in quantitative analysis, creatinine at gradient concentration and deuterated creatinine at fixed concentration are added into an urine sample, direct analysis is performed, a standard addition curve is drawn, and the concentration of the urine creatinine is obtained. The urine creatinine can be directly measured under the condition that the sample is not pretreated, and the defects of a long analysis period and low efficiency in the prior art are overcome. The method has the characteristics of quickness, accuracy, capability of resisting interference from a substrate, and the like, and is particularly suitable for the clinical research of renal disease (such as the early diagnosis of acute renal failure) and high-flux sample analysis.

The invention relates to new application of small molecular metabolites caffeine, creatinine, eicosamide, phenylacetylglutamine, decanoic acid and indolelactic acid in a plasma sample as combined markers in preparation of a kit for diagnosing Parkinson's disease patients in subjects. The invention also relates to the kit for detecting the Parkinson's disease patients in the subjects, and the kit is used for calculating the variables of the combined markers based on a binary logistic regression equation by detecting the respective relative concentrations of the combined markers in the plasma from the subjects, and judging whether the subjects suffer from Parkinson's disease or not based on determined intercept values. The kit can realize high-sensitivity detection of several metabolites involved in the invention, and has the characteristics of low detection cost and good repeatability. The combined use of the small molecule metabolites can be used for assisting the clinical diagnosis ofthe Parkinson's disease, and has higher development and application values.

The invention belongs to the technical field of clinical biological sample detection, and particularly relates to a method for detecting trimethylamine oxide, choline, betaine, creatinine and L-carnitine in a biological sample through high-throughput liquid chromatography-tandem mass spectrometry. The method can simultaneously detect five substances in a biological sample, and has the advantages of high accuracy, high sensitivity, high specificity, small required sample volume, simple sample pretreatment, good tolerance and the like.

The invention belongs to the chemical field of natural products and in particular relates to an extraction method and an application of moringa oleifera leaf total flavones. The extraction method adopts microwave and ultrasound to synergistically extract the moringa oleifera leaf total flavones, and has the advantages of high efficiency, time saving, energy conservation, low energy consumption, simple operation and good repeatability. Besides, an animal test proves that the extracted moringa oleifera leaf total flavones have a significant treatment effect on hyperuricosuria and Alzheimer's disease. The total flavones provided by the invention can reduce uric acid, and can also reduce cholesterol, triacylglycerol, urea nitrogen, creatinine and xanthine oxidase, reduce the generation of uric acid, directly decompose uric acid, improve the renal function, promote uric acid excretion, and protect multiple levels of blood vessels to reduce uric acid, so that the moringa oleifera leaf total flavones are beneficial for healing of lithemia patients and have a broad medical application prospect.

The invention discloses a gold nanoparticle (AuNPs) biological sensor for detecting serum creatinine and a preparation method of the gold nanoparticle biological sensor. The preparation method comprises the steps of (1) preparing an AuNPs solution; (2) adding a GSH solution serving as an anti-aggregating agent for uniform mixing, and performing surface protection on the AuNPs; and (3) respectively adding standard serum creatinine solutions with different concentrations, and performing colorimetric and quantitative detection by using a fluorospectro photometer to obtain a relation curve between the serum creatinine concentration and the resonance light scattering (RLS) intensity so as to obtain the gold nanoparticle biological sensor. GSH can form a protection layer on the surface of AuNPs, so that the aggregation degree of AuNPs, which is caused by the adding of the serum creatinine is reduced; under proper GSH concentration, the serum creatinine solutions with different concentrations are added, so that an AuNPs solution system shows a gradual color change phenomenon; meanwhile, by the use of the relation between an AuNPs dispersing state or the aggregating degree and the RLS intensity, quantitative detection on the serum creatinine can be realized. The method for visual measurement and RLS intensity detection on the serum creatinine has the advantages of simplicity, quickness, high practicability and the like.

The invention relates to a urinary microalbumin (U-mALb) / urinary creatinine (U-Cr) integrated assay bigeminy strip, comprising a sample area and reaction areas. The U-mALb / U-Cr integrated assay bigeminy strip is characterized in that the sample area comprises a diffusion membrane and blood filtering membranes; the reaction areas comprise two detection windows, and the two detection windows can be used for detecting the ratios of the U-mALb and the U-Cr at the same time; the sample area for detecting the U-Cr by adopting a dry chemical method is arranged at the position where the reaction area is positioned, and the reaction area for detecting the U-mALb by using a colloidal gold dry type immune chromatography technology is arranged at a position which is 0.5cm away from the sample area. The different reaction areas contain different reagent pads, and the reagent pads respectively and independently react with corresponding components in urine. Synchronous detection can be realized only by dripping the random urine of a person to be tested into the sample area, so that the U-mALb / U-Cr integrated assay bigeminy strip is very suitable for medical institutions or individuals. By using the U-Cr for correction, the influence, caused by a sampling way and urine volume, on the excretory amount of urinary albumin can be eliminated, so that the U-mALb / U-Cr integrated assay bigeminy strip can provide more accurate evaluation for the albumin excretion rate and has a greater clinical significance for preventing diabetic nephropathy.

The invention is about a method of measuring the content of creatinine, and it also concerns the reagent box of creatinine diagnosis. This invention belongs to the field of medical testing and measuring technology. The reagent box is consisted of buffer solution, creatinine enzyme, creatine enzyme, sarcosine onidase, anaerooxidase and stabilizer. Firstly, we cause an enzyme-coupled reaction through mixing the sample and the reagent according to a certain proportion of volume; secondly, put the final reactant under the biochemical analyzer and test the absorbance variational situation (speed) of dominant wavelength; then we can get the content of creatinine. By using this invention, we can get the necessary measuring result with high sensitiveness and fine precision through biochemical analyzer, and the result would not be contaminated by material of internal and exogenous sources. Thus, this method can be conveniently promoted and applied.

Provided are methods and compositions for predicting the development of kidney disease, including acute kidney injury. In certain aspects and embodiments the provided methods and compositions are particularly useful for predicting kidney injury following an event likely to cause kidney injury and / or kidney failure in a patient, such as a cardiac surgery, e.g., a surgery involving a cardiopulmonary bypass (CPB), such as a coronary artery bypass graft surgery. In some embodiments, the higher the urinary hepcidin-to-urinary creatinine ratio (uHep / uCr) at 6-24 hours following initiation of CPB, the lower is the risk for development of AKI determined by RIFLE criteria in the ensuing four to five days. Conversely, the higher the urinary NGAL to urinary creatinine ratio (uNGAL / uCr) at 6-24 hours following initiation of CPB, the higher is the risk of developing CPB-mediated AKI over the same time period.

The invention relates to a technological method for catalyzing lactic acid and glycollic acid into copolycondensation by a biomass creatinine so as to synthesize a medical biodegradable material polylactic acid-glycollic acid. With the arginine metabolite creatinine in human body as the catalyst, industrial lactic acid (LA, 85% aqueous solution) and glycollic acid (GA, 95%) as comonomers, the medical degradable material polylactic acid-glycollic acid of high biological safety can be obtained through solvent-free and two-step bulk copolycondensation. The invention has the characteristics of green technology, low raw material cost, simple operation and easy industrial implementation; the catalyst creatinine is of high biocompatibility and biological safety and is free of cytotoxicity, and the synthesized polylactic acid-glycollic acid contains no metal and other toxic residues; the synthesized polylactic acid-glycollic acid has a molecular weight adjustable in the range of 1.8-17.7*104; and the synthesized polylactic acid-glycollic acid of the invention is suitable to be used as implanted hard tissue repairing materials, surgical sutures, targeting and controlled release drug carriers.

A method of detecting creatinine in body fluids using an indicator which produces a fluorescent response when oxidized in the presence of a copperII / creatinine complex. A preferred indicator is 4-(1-methylhydrazino)-7-nitro benzooxadiazole (MNBDH).

The invention discloses an evaluation method for diet protein intake (DPI) of a chronic kidney disease (CKD) patient. Through research of relationships between a fasting serum blood urea nitrogen / creatinine ratio (BUN / Cr) and a single-time urine urea nitrogen / creatinine ratio (UUN / Cr) of a CKD third-phase patient with a stable illness state, and the diet protein intake (DPI), a DPI simple calculation formula based on the fasting serum BUN / Cr and / or random urine UUN / Cr is established. According to the final calculation formula, it is expected that a traditional method for evaluating the DPI through subsistence of the urine within 24 hours can be replaced by a biochemical detection result of a single-time blood or urine in clinical follow-up. Defects such as complexity, long detection time, poor accuracy, difficult sample subsistence or low patient compliance in the traditional method are overcome. Clinically, the method can be used for clinical follow-up, simple blood drawing or single-time urination, thereby evaluating the DPI. The method can be used for managing the diet protein intake of the CKD patient well, fast and conveniently.

The embodiment of the invention discloses a human serum creatinine content detecting reagent for resisting calcium dobesilate interference. The detection reagent comprises a first reagent, a second reagent and a third reagent, wherein the first reagent comprises sodium carbonate. The detection reagent is used for determining human serum creatinine based on an enzyme method, and besides, interference of calcium dobesilate drugs in serum can be avoided. The defect for detecting creatinine by a conventional enzyme method is overcome. The embodiment of the invention further provides a human serumcreatinine content detecting method for resisting calcium dobesilate interference.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.